LENZ Therapeutics, Inc.

NASDAQ: LENZ · Healthcare · Biotechnology

PublicHQ Solana Beach, CA · San DiegoCIK 0001815776Reports USD

#547 of 1,394 Healthcare companies by revenue

EA Score

47D

FH 57DQ 35GM —SS 31

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$21.0M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$82.1M

Employees

Market cap

$184.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$19.1M$19.1M2025

Net income-$82.1M-$82.1M2025

Operating income-$91.1M-$91.1M2025

Total assets$305.9M$305.9M2025

Liabilities$21.5M$21.5M2025

Equity$284.3M$284.3M2025

Revenue by segment

Filed disclosures · FY2025

By product

License92%

Product8%

By geography

Not disclosed.

The read

LENZ Therapeutics, Inc. booked $19.1M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -430.3% net margin.

Peers · Healthcare

Panamera Holdings Corporation31D Quantum-Si incorporated40D Evommune, Inc.44D Surrozen, Inc.30D

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Sempra$12.4B64C Realty Income Corporation$5.7B59C ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+DexCom, Inc.$4.7B87A

Key facts

CEOEvert Schimmelpennink

SectorHealthcare

IndustryBiotechnology

HeadquartersSolana Beach, CA

ExchangeNASDAQ: LENZ

Employees6

IPO date2024-03-22

Latest filings

8-K2026-07-02 8-K2026-06-12 10-Q2026-05-11 8-K2026-05-11 DEF 14A2026-04-28 8-K2026-03-24 10-K2026-03-24 8-K2026-01-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.